Cathie Wood’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cathie Wood’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,228	Closed	-$167K	–	262
2022 Q2	$167K	Sell	2,228 -106	-5%	-$8.44K	﹤0.01%	270
2022 Q1	$180K	Buy	+2,334	New	+$195K	﹤0.01%	292
2017 Q1	–	Sell	-960	Closed	-$80K	–	106
2016 Q4	$80K	Buy	+960	New	+$82.6K	0.03%	91

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Cathie Wood's BMRN Position: Q3 2022 in Review

Cathie Wood sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 2,228 shares — an estimated $167K sold.

Cathie Wood first reported a position in BMRN in Q4 2016 and held it in 3 quarters. The position peaked at $180K in Q1 2022. 552 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Cathie Wood reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Cathie Wood sold 2,228 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $167K.
Cathie Wood first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 3 quarters.
Cathie Wood's BioMarin Pharmaceuticals position peaked at $180K in Q1 2022.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on ARK Investment Management's 13F filing for Q3 2022, filed 17 Oct 2022.